Dr Chong Kian Tai is an experienced urologist, specialising in the diagnosis, management and treatment of prostate, kidney, bladder, testis, and penile cancers.

In 2009, Dr Chong obtained his advanced clinical urologic-oncology fellowship at the prestigious Memorial-Sloan Kettering Cancer Center (MSKCC) in New York, USA and was the first urologist trained in Southeast Asia to complete this fellowship at the MSKCC. He is well-versed in traditional open surgeries, advanced keyhole laparoscopic and endoscopic surgeries and the modern Da Vinci robotic surgical operating systems.

For urological cancers, Dr Chong concentrates on Da Vinci robotic partial nephrectomy for kidney cancer, Da Vinci robotic radical prostatectomy for prostate cancer with removal of pelvic lymph nodes, focal therapy for early-stage prostate cancer, MRI-ultrasound fusion prostate biopsy and bladder cystoscopy with narrow-band imaging (NBI) to better detect bladder cancer. For general urology, he focuses on enlarged prostate, also known as benign prostate hyperplasia (BPH), and retrograde intrarenal surgery for laser treatment of kidney stones (RIRS).

Dr Chong’s previous appointments include consultant, adjunct assistant professor, co-director of urologic oncology and director of research of the Department of Urology at Tan Tock Seng Hospital (TTSH), where he also managed the urology cancer clinical databases and tissue repository. His dedication to improving prostate cancer awareness and survivorship led him to serve as an advisory panel member at the Singapore Cancer Society. With a passion for patient welfare, Dr Chong held several significant roles in TTSH including chairman of the Urology Cancer Multidisciplinary Tumour Board, Urology Cancer Support Programme, Advanced Care Planning Team and TTSH Prostate Cancer Support Group.

As a healthcare innovator, researcher and educator, Dr Chong embarked on molecular research in urologic-oncology on prostate cancer immunology in Seattle, Washington, USA, which was funded by Southwest Oncology Group and Agency for Science, Technology and Research (A*STAR) in Singapore. While in Singapore, he played a pivotal role as a founding member of the Singapore Urological Cancer Consortium, overseeing several teams dedicated to prostate, kidney, bladder and testis cancer research. These projects included precision medicine, biomolecular, nanoparticle, bioimaging and novel biomedical device studies.

Dr Chong accepts referrals for all urological conditions, with a special clinical interest in prostate, kidney, bladder, testis, and penile cancers.